InflaRx (NASDAQ:IFRX) Announces Earnings Results, Misses Estimates By $0.04 EPS

InflaRx (NASDAQ:IFRX) released its quarterly earnings results on Thursday. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04), Zacks reports.

InflaRx Price Performance

NASDAQ:IFRX traded up $0.12 during trading hours on Friday, hitting $1.84. The company’s stock had a trading volume of 1,167,412 shares, compared to its average volume of 890,553. InflaRx has a twelve month low of $0.78 and a twelve month high of $2.95. The stock has a fifty day simple moving average of $1.89 and a 200-day simple moving average of $1.53. The company has a market capitalization of $133.01 million, a P/E ratio of -3.17 and a beta of 2.48.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a research report on Wednesday, June 24th. Wall Street Zen upgraded shares of InflaRx from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Oppenheimer initiated coverage on InflaRx in a research report on Friday, April 24th. They set an “outperform” rating and a $5.00 price target on the stock. Raymond James Financial upgraded InflaRx from an “outperform” rating to a “strong-buy” rating and raised their price objective for the stock from $7.00 to $9.00 in a research note on Wednesday, May 13th. Finally, HC Wainwright lifted their price objective on InflaRx from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, May 11th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $7.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in IFRX. Cubist Systematic Strategies LLC increased its holdings in shares of InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after buying an additional 7,616 shares in the last quarter. Boothbay Fund Management LLC grew its position in InflaRx by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock worth $235,000 after acquiring an additional 17,056 shares during the last quarter. Squarepoint Ops LLC increased its holdings in InflaRx by 29.1% in the 3rd quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock worth $253,000 after purchasing an additional 42,489 shares in the last quarter. HRT Financial LP bought a new position in InflaRx in the fourth quarter valued at about $47,000. Finally, Insigneo Advisory Services LLC acquired a new stake in shares of InflaRx during the fourth quarter valued at about $61,000. Institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.